Compare State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF (FLRN) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF vs 10X Genomics Inc — how do they compare? State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.76 (market cap $3.06B), while 10X Genomics Inc trades at $79 (market cap $10.07B). The key difference: 10X Genomics Inc is far larger — about 3.3× State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF's market cap, and 10X Genomics Inc is trading nearer its 52-week high, State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF for 15 Days and 10X Genomics Inc for 92 Days on average.
| FLRN | TXG | |
|---|---|---|
Market Cap | $3.06B | $10.07B |
Volume | 6,296,473 | 5,657,286 |
Sector | Fixed Income | Health |
52-Week High | $30.86 | $97.74 |
52-Week Low | $30.65 | $11.48 |
Typical Hold Time | 15 Days | 92 Days |
Enterprise Value | — | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLRN (SPDR Bloomberg Investment Grade Floating Rate ETF) trades at $30.75 with minimal daily movement (+0.03%). Technical indicators show a bearish trend with strong selling pressure in moving averages, while oscillators remain neutral. The ETF maintains consistent $0.11 quarterly dividend payments through 2026, providing income stability amid current market volatility.
FLRN offers protection against rising interest rates with near-zero duration exposure, though significant financial sector concentration presents risk. Current market sentiment reflects cautious optimism as institutional investors add positions while technical indicators suggest near-term pressure. The floating rate structure positions FLRN favorably in inflationary environments.
10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.
TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF
FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.
Read more on FLRN →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
